A Study to Investigate Multiple Ascending Doses and Relative Bioavailability of AZD5004 in Healthy Participants

AstraZeneca31 enrolled

Overview

The main purpose of this study is to assess the safety, tolerability, and pharmacokinetic (PK) of AZD5004 administered as multiple oral doses in healthy participants and to compare the relative bioavailability of two oral tablet strengths of AZD5004.

This study comprises of 2 parts - Part A and Part B. Part A is a placebo-controlled study to assess the safety, efficacy, tolerability, and PK of repeated dosing of AZD5004 compared with placebo. Participants who are eligible according to the inclusion/exclusion criteria will be randomized to receive AZD5004 or matching placebo. Part A will comprise: 1. A Screening Period of maximum 28 days. 2. A Treatment Period of 106 days. 3. A final Follow-up Visit approximately 14 days after the last study intervention administration. Part B is a two-way cross-over study to compare the relative bioavailability of 2 oral tablet strengths of Formulation 1 (F1) of AZD5004. The purpose of this study is to expand product knowledge between the 2 oral tablet strengths on plasma exposure levels to guide Phase 3 drug product development. The participants will be split into 2 groups. Group 1 will be dosed with Treatment 1 of AZD5004 and then dosed with Treatment 2 of AZD5004. Group 2 will be dosed with Treatment 2 of AZD5004 and then dosed with Treatment 1 of AZD5004. Part B of the study will comprise: 1. A Screening Period of maximum 28 days. 2. Two Treatment Periods, each consisting of 7 days. 3. A final Follow-up Visit approximately 6 days after the last dose of study intervention administration.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Healthy Participants

Interventions

AZD5004DRUG

Participants will receive oral tablets of AZD5004 in Part A and Part B of the study as per arms they are assigned.

PlaceboDRUG

Placebo will be administered as an oral tablet once daily.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Must have suitable veins for cannulation or repeated venipuncture. * Female(s) of Childbearing Potential must use adequate contraception (oral contraceptives are not permitted). * Have a BMI ≥ 23 kg/m2 and not exceeding 35 kg/m2 inclusive and weigh at least 60 kg. * No or off statin treatment for ≥ 4 weeks prior to the study treatment. Exclusion Criteria: * History of any clinically important disease or disorder. * History of acute pancreatitis, chronic pancreatitis, gallstones, or elevation in serum lipase/pancreatic amylase. * History or presence of gastrointestinal, hepatic, or renal disease. * Clinically significant hepatic disease, inflammatory bowel disease, gastroparesis, severe disease, or surgery affecting the upper gastrointestinal tract. * Any clinically important abnormalities in clinical chemistry, hematology, or urinalysis results. * Any clinically important abnormalities in rhythm, blood pressure, heart rate, conduction or morphology of the resting electrocardiogram (ECG). * Uncontrolled thyroid disease, defined as thyroid-stimulating hormone \> 6.0 mIU/L or \< 0.4 mIU/L at Screening. * Current smokers or known history of alcohol or drug abuse. * History of severe allergy/hypersensitivity or excessive intake of caffeine-containing drinks or food. * Use of any prescribed or nonprescribed medication including antacids or analgesics. * Participants who are on or are planning to undertake a weight loss program. * History of psychosis, major depressive disorder, suicide attempt or suicidal ideation within the past year. * Lactating, breastfeeding, or pregnant females or females who intend to become pregnant. * Participants who are vegans or have medical dietary restrictions.

Locations (1)

Research Site

Brooklyn, Maryland, United States

Outcomes

Primary Outcomes

Part A: Number of participants with adverse events (AEs) and serious adverse events (SAEs)

To assess the safety and tolerability of AZD5004 following oral multiple ascending doses in healthy participants.

Time frame: From screening (Day -28) to last follow up visit (Day 120)

Part B: Maximum observed plasma (peak) drug concentration (Cmax) of AZD5004

To evaluate the Cmax of 2 treatments of AZD5004 in healthy participants.

Time frame: From Day 1 (Treatment Period 1) to Day 13 (end of Treatment Period 2)

Part B: Area under the concentration-curve from time zero to the last quantifiable concentration (AUClast)

To evaluate the AUClast of 2 treatments of AZD5004 in healthy participants.

Time frame: From Day 1 (Treatment Period 1) to Day 13 (end of Treatment Period 2)

Part B: Area under concentration-time curve from time 0 to infinity (AUCinf)

To evaluate the AUCinf of 2 treatments of AZD5004 in healthy participants.

Time frame: From Day 1 (Treatment Period 1) to Day 13 (end of Treatment Period 2)

Part B: Time to reach maximum observed concentration (tmax)

To evaluate the tmax of 2 treatments of AZD5004 in healthy participants.

Time frame: From Day 1 (Treatment Period 1) to Day 13 (end of Treatment Period 2)

Secondary Outcomes

Part A: Maximum observed plasma (peak) drug concentration (Cmax) of AZD5004

To characterize the Cmax of multiple ascending doses of AZD5004 in healthy participants.

Time frame: From Day 1 to last follow up visit (Day 120)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.